Updated time: 2022-06-09 09:10:49
PD-L1 expressed on many solid tumors is the ligand of immune inhibitory receptor PD-1. The engagement of PD-L1 to PD-1 triggers immunosuppressive pathways and impairs anti-tumor activities of immune cells. The antagonistic PD-L1 aptamer described in this patent will block the interaction between PD-L1 and PD-1 and induce the anti-tumor activities in immune cells.
Until now, the main targeted therapeutic agents against PD-L1 are monoclonal antibodies. Compared to traditional protein-based drugs, the DNA-based PD-L1 aptamer described in this patent has higher stability and lower cost for large scale synthesis. Moreover, this PD-L1 aptamer could be easily chemical modified to enhance bioavailability with little batch effect.
12A-1040126
US 10584341 B2、TW I721008、EP 3344772、CN ZL201680050589.3
Cancer therapy, immunotherapy
Pan-Chyr Yang, Wei-Yun Lai, Yi-Chung Chang, Bo-Tsang Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

An antagonistic PDL1 aptamer and its applications in cancer therapy